Were Henry Pelish’s Nuvalent (NUVL) share sales made under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state that Henry Pelish’s transactions were effected pursuant to a Rule 10b5-1 trading plan. That plan was adopted on December 11, 2025, indicating the sales were pre‑scheduled rather than newly decided at the time of execution.

Nuvalent CSO exercises options, sells 35,104 shares

Q: How many Nuvalent (NUVL) shares did CSO Henry Pelish sell and at what prices?

Henry Pelish sold 35,104 Nuvalent shares in several open-market transactions. Reported weighted average sale prices were in the high $90s, with individual trades occurring in ranges from $97.08–$100.14 per share, as detailed across multiple weighted-average price footnotes in the Form 4.

Q: What stock options did Henry Pelish exercise in this Nuvalent (NUVL) filing?

Pelish exercised Nuvalent stock options covering 17,320 shares of Class A Common Stock. These options carried exercise prices of $18.93, $27.85, $29.33, and $72.35, with expiration dates extending from January 2022-style through January 5, 2034, as specified for each grant.

Q: What pattern of activity does Henry Pelish’s Nuvalent (NUVL) Form 4 show?

The filing shows an exercise-and-sell pattern. Pelish exercised Nuvalent stock options for 17,320 shares and then sold 35,104 shares in the open market at prices mostly in the high $90s, all under a pre-established Rule 10b5-1 trading plan.

Nuvalent, Inc.’s Chief Scientific Officer Henry E. Pelish exercised stock options and sold shares of Class A Common Stock in mid-March 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Nuvalent, Inc.’s Chief Scientific Officer Henry E. Pelish exercised stock options and sold shares of Class A Common Stock in mid-March 2026. He exercised options covering 17,320 shares at strike prices between $18.93 and $72.35, converting them into common shares.

On March 12–13, 2026, he then executed open-market sales totaling 35,104 shares at weighted average prices around the high‑$90s, in multiple trades across price ranges from $97.08 to $100.14. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. After these transactions, Pelish directly holds 65,604 shares of Nuvalent Class A Common Stock.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 14 txns

Insider Pelish Henry E.

Role Chief Scientific Officer

Sold 35,104 shs ($3.44M)

Approx. gross sale proceeds $3.44M

Approx. exercise cost $546K

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	804	$97.89	$79K
Sale	Class A Common Stock	2,597	$98.83	$257K
Sale	Class A Common Stock	1,703	$99.71	$170K
Exercise	Stock Option (Right to Buy)	8,456	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	1,754	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	4,125	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	2,985	$0.00	$0.00
Exercise	Class A Common Stock	8,456	$18.93	$160K
Exercise	Class A Common Stock	1,754	$27.85	$49K
Exercise	Class A Common Stock	4,125	$29.33	$121K
Exercise	Class A Common Stock	2,985	$72.35	$216K
Sale	Class A Common Stock	24,189	$97.79	$2.37M
Sale	Class A Common Stock	5,505	$98.44	$542K
Sale	Class A Common Stock	306	$99.12	$30K

Holdings After Transaction: Stock Option (Right to Buy) — 44,488 contracts (Direct); Class A Common Stock — 65,604 shares (Direct)

Footnotes (10)

F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025.
F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.08 to $98.07, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) of this Form 4.
F3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.08 to $99.07, inclusive.
F4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.19 to $98.16, inclusive.
F5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.19 to $99.12, inclusive.
F6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.21 to $100.14, inclusive.
F7. The shares underlying this option are fully vested.
F8. The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
F9. The shares underlying this option have vested or shall vest over the four years following March 1, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
F10. The shares underlying this option have vested or shall vest over the four years following January 5, 2024 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nuvalent (NUVL) disclose in Henry Pelish’s latest Form 4?

Nuvalent reported that Chief Scientific Officer Henry E. Pelish exercised stock options for 17,320 shares and sold 35,104 shares of Class A Common Stock in open-market transactions. Following these trades, he directly holds 65,604 Nuvalent shares according to the Form 4 data.

How many Nuvalent (NUVL) shares did CSO Henry Pelish sell and at what prices?

Henry Pelish sold 35,104 Nuvalent shares in several open-market transactions. Reported weighted average sale prices were in the high $90s, with individual trades occurring in ranges from $97.08–$100.14 per share, as detailed across multiple weighted-average price footnotes in the Form 4.

What stock options did Henry Pelish exercise in this Nuvalent (NUVL) filing?

Pelish exercised Nuvalent stock options covering 17,320 shares of Class A Common Stock. These options carried exercise prices of $18.93, $27.85, $29.33, and $72.35, with expiration dates extending from January 2022-style through January 5, 2034, as specified for each grant.

How many Nuvalent (NUVL) shares does Henry Pelish own after these transactions?

After completing the reported option exercises and open-market sales, Henry Pelish directly owns 65,604 shares of Nuvalent Class A Common Stock. This post-transaction holding figure is taken from the Form 4 line showing total shares beneficially owned following the latest sale entry.

What pattern of activity does Henry Pelish’s Nuvalent (NUVL) Form 4 show?

The filing shows an exercise-and-sell pattern. Pelish exercised Nuvalent stock options for 17,320 shares and then sold 35,104 shares in the open market at prices mostly in the high $90s, all under a pre-established Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/16/2026 - 04:31 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pelish Henry E.

(Last)

(First)

(Middle)

C/O NUVALENT, INC.

ONE BROADWAY, 14TH FLOOR

(Street)

CAMBRIDGE

02142

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvalent, Inc. [ NUVL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	03/12/2026		M⁽¹⁾		8,456	A	$18.93	91,844	D
Class A Common Stock	03/12/2026		M⁽¹⁾		1,754	A	$27.85	93,598	D
Class A Common Stock	03/12/2026		M⁽¹⁾		4,125	A	$29.33	97,723	D
Class A Common Stock	03/12/2026		M⁽¹⁾		2,985	A	$72.35	100,708	D
Class A Common Stock	03/12/2026		S⁽¹⁾		24,189	D	$97.79⁽²⁾	76,519	D
Class A Common Stock	03/12/2026		S⁽¹⁾		5,505	D	$98.44⁽³⁾	71,014	D
Class A Common Stock	03/12/2026		S⁽¹⁾		306	D	$99.12	70,708	D
Class A Common Stock	03/13/2026		S⁽¹⁾		804	D	$97.89⁽⁴⁾	69,904	D
Class A Common Stock	03/13/2026		S⁽¹⁾		2,597	D	$98.83⁽⁵⁾	67,307	D
Class A Common Stock	03/13/2026		S⁽¹⁾		1,703	D	$99.71⁽⁶⁾	65,604	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$18.93	03/12/2026		M⁽¹⁾			8,456	⁽⁷⁾	01/04/2032	Class A Common Stock	8,456	$0.00	2,113	D
Stock Option (Right to Buy)	$27.85	03/12/2026		M⁽¹⁾			1,754	⁽⁸⁾	01/06/2033	Class A Common Stock	1,754	$0.00	11,402	D
Stock Option (Right to Buy)	$29.33	03/12/2026		M⁽¹⁾			4,125	⁽⁹⁾	03/01/2033	Class A Common Stock	4,125	$0.00	9,900	D
Stock Option (Right to Buy)	$72.35	03/12/2026		M⁽¹⁾			2,985	⁽¹⁰⁾	01/05/2034	Class A Common Stock	2,985	$0.00	21,073	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.08 to $98.07, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) of this Form 4.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.08 to $99.07, inclusive.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.19 to $98.16, inclusive.

5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.19 to $99.12, inclusive.

6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.21 to $100.14, inclusive.

7. The shares underlying this option are fully vested.

8. The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

9. The shares underlying this option have vested or shall vest over the four years following March 1, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

10. The shares underlying this option have vested or shall vest over the four years following January 5, 2024 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

	/s/ Nathan N. McConarty, attorney-in-fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR